A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by Peripheral Nerve Excitability Testing (NET)
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Lacosamide (Primary) ; Pregabalin (Primary) ; Tapentadol (Primary)
- Indications Epilepsy; Pain; Partial epilepsies; Tonic-clonic epilepsy
- Focus Pharmacodynamics
- 22 Jul 2022 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.
- 20 Feb 2022 Status changed from recruiting to completed.
- 10 Sep 2019 New trial record